$0.16
+0.01 (+4.55%)
Open$0.16
Previous Close$0.15
Day High$0.16
Day Low$0.15
52W High$1.43
52W Low$0.13
Volume—
Avg Volume1.36M
Market Cap12.62M
P/E Ratio—
EPS$-0.57
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,738.5% upside
Current
$0.16
$0.16
Target
$9.40
$9.40
$5.45
$9.40 avg
$11.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.96M | 2.16M | 1.98M |
| Net Income | -107,565,690 | -609,365 | -497,914 |
| Profit Margin | -634.3% | -28.2% | -25.1% |
| EBITDA | -112,575,189 | -937,252 | -843,277 |
| Free Cash Flow | — | -606,690 | -515,846 |
| Rev Growth | +194.7% | +2.0% | +14.6% |
| Debt/Equity | — | 0.62 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |